Curi Bio

About Curi Bio

Curi Bio is a life sciences company providing advanced platforms to accelerate the discovery of new medicines. Founded in 2015 as NanoSurface Biomedical, the company rebranded to Curi Bio in 2020 to reflect its expanded strategy. The initial founding team included Elliot Fisher and his former research advisor at the University of Washington, Deok-Ho Kim. The leadership team includes CEO Dr. Nicholas Geisse and CSO Michael Cho, JD. Dr. Geisse has an extensive background in pharmacology and tissue engineering from institutions like Cambridge University and Harvard, while Mr. Cho has a legal and corporate strategy background.

The company serves the pharmaceutical and biotechnology sectors, with a client roster that includes all top-ten global pharmaceutical companies. Its business model centers on providing a three-pronged platform known as the Curi Engine™, which integrates human induced pluripotent stem cells (iPSCs), tissue-specific biosystems, and AI/ML-enabled data analysis. This approach aims to close the gap between preclinical results and clinical outcomes by creating more predictive, human-relevant models of disease. Revenue is generated through the sale of its proprietary products and customized research services, including assay development and phenotypic screening.

Curi Bio's product suite enables scientists to build mature 3D engineered tissues, with a specific focus on cardiac, skeletal muscle, and neuromuscular models. Key products include the Mantarray™ platform for analyzing the contractility of 3D engineered muscle tissues, NanoSurface™ Plates which promote structural cell maturation, and the Cytostretcher™ instrument for cell-stretching experiments. These systems provide clinically-relevant functional data, intending to reduce the industry's reliance on less predictive animal models. The company has secured significant funding through multiple rounds, including over $21 million from grants and Series A financing, to scale its operations and advance platform development. Strategic milestones include the acquisition of Silene Biotech in 2019 and Dana Solutions in 2020, as well as forming a joint venture, Celogics, with NEXEL in 2021.